If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Sublocade (buprenorphine) is a brand-name subcutaneous injection prescribed for opioid use disorder. It works to help reduce the need for opioids by acting in certain areas of the brain called mu and ...

Sublocade (buprenorphine) is a prescription drug that’s used to treat opioid use disorder. Sublocade can cause side effects that range from mild to serious. Examples include injection site reaction, ...

Sublocade (buprenorphine) is a brand-name prescription medication. The Food and Drug Administration (FDA) has approved it to treat opioid use disorder in adults, as part of a complete treatment ...

The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) These FDA ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition ...